ARMP
- Armata Pharmaceuticals, Inc.
()
Overview
Company Summary
Armata Pharmaceuticals, Inc. (ARMP) is a biotechnology company that focuses on the development and commercialization of bacteriophage-based therapeutics to address multidrug-resistant bacterial infections.
Bacteriophages, or phages, are natural viruses that can specifically target and kill bacteria. Armata is leveraging this unique ability of phages to develop novel therapies that combat antibiotic-resistant bacteria, which pose a significant global health threat.
The company's platform technology involves identifying and isolating potent phages that are effective against specific bacterial strains. These phages can be designed to destroy bacteria directly or modify them to enhance the effectiveness of antibiotics. Armata also develops phage cocktails, which consist of multiple phages targeting different bacteria within the same infection, to increase treatment efficacy.
Armata's product pipeline includes candidates for diverse infections caused by multidrug-resistant pathogens, such as Escherichia coli (E. coli), Pseudomonas aeruginosa, and Staphylococcus aureus (S. aureus). Their lead candidate, AP-PA02, is being developed for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis patients.
In addition to its clinical development efforts, Armata collaborates with academic institutions and government agencies to advance the understanding and application of phage-based therapeutics. The company is dedicated to addressing the urgent medical need for novel strategies to combat antibiotic resistance and improve patient outcomes.
Please note that the information provided here is a general overview, and for a more comprehensive understanding of Armata Pharmaceuticals' activities, it is recommended to refer to the company's official website and regulatory filings.